ABOS
Acumen Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.23
−3.88%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.23
From 52W high−93.31%
Volume6.80M
Market cap$16.30M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.23
From 52W high
−93.31%
Volume
6.80M
Market cap
$16.30M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
P/E (TTM)
—
RSI (14)
21.0
MomentumView details →
1D Return
−3.88%
YTD Return
−89.10%
SummaryUpdated Sep 1, 2026
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is a clinical-stage biopharmaceutical company founded in 1996 and headquartered in Charlottesville, Virginia. The company went public in July 2021 and focuses exclusively on developing innovative treatments for Alzheimer's disease. Acumen has spent over two decades researching and developing targeted immunotherapy approaches, with its lead drug candidate sabirnetug (formerly ACU193) currently in Phase 2 clinical trials. The company represents a specialized player in the competitive Alzheimer's therapeutics landscape, pursuing a differentiated approach by targeting toxic amyloid-beta oligomers rather than amyloid plaques.
Similar companies
Latest newsMore news →
Acumen Pharmaceuticals, Inc. said it is targeting a mid-2027 IND filing for the lead clinical candidate in its Enhanced Brain Delivery program.9d agoAcumen Pharmaceuticals, Inc. said it expects to report topline results from its Phase 2 ALTITUDE-AD study of sabirnetug (ACU193) in November 2026.9d agoAcumen Pharmaceuticals, Inc. announced that it will present three posters on its Phase 2 ALTITUDE-AD trial at the CTAD conference in Boston.13d ago